Thursday, April 30, 2020

MissionIRNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Featured in Dougherty & Company LLC Research Report


Trxade Group (NASDAQ: MEDS) was featured in a recent equity research report published by Dougherty & Company LLC. The report reads, “We are initiating coverage of Trxade with a Buy rating and Price Target of $12. MEDS’ primary offering is a web-based platform connecting large suppliers of branded and generic drugs with retail and independent pharmacies. The platform offers full price transparency, comparing the prices and availability across a variety of suppliers. Its latest offering is a direct-to-consumer application equipped with telemedicine visits which includes home delivery of medications. MEDS nearly doubled revenue in 2019 and we model the company increasing sales at close to a 40% clip in 2020, while profitable for several quarters. We view the stock as a compelling, under-the-radar idea for small-cap growth investors seeking exposure to digital health and telemedicine. Our $12 Price Target is based on a 6x multiple on our 2021 forecast, a slightly lower multiple than comps which we justify with a small cap discount, but considering also MEDS’ superior growth rate.”

To request access to the full report, visit http://ibn.fm/LQ1QX

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASQAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to buyers and sellers of pharmaceuticals, makes healthcare services affordable and accessible across all 50 states, and steps in to meet today’s immediate demands. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms; the Trxade B2B trading platform with 12,100 registered pharmacies, a licensed virtual Wholesaler, affordable healthcare via its Bonum Health app or web-based telehealth services, and same day or mail order pharmacy delivery capabilities via its DelivMeds app featuring its extensive nationwide distribution network. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html